Cefuroxime

Transcripción

Cefuroxime


Home

> Martindale: The Complete Drug Reference

> Drugs and Ancillary Substances

> By therapeutic use

> Antibacterials

> Drug Monographs
Cefuroxime
Sub-sections

Cefuroxime

Cefuroxime Axetil

Cefuroxime Sodium

Adverse Effects and Precautions

Interactions

Antimicrobial Action

Pharmacokinetics

Uses and Administration

Preparations
Cefuroxime
Date of monograph review: 07-Apr-1997; 20-Jul-1998; 06-Oct-1999; 02Oct-2001; 12-Nov-2003; 25-Jul-2006; 10-Sep-2008; 20-Nov-2009; 20-Aug2010; (latest modification: 13-May-2013)
Drug Nomenclature (Latest modification: 13-May-2013)
Synonyms: 640/359; Κεφουροξίμη; Cefuroxim; Cefuroxima;
Cefuroximum; Kefuroksiimi; Sefuroksim; セフロキシム
BAN: Cefuroxime
USAN: Cefuroxime
INN: Cefuroxime [rINN (en)]
INN: Cefuroxima [rINN (es)]
INN: Céfuroxime [rINN (fr)]
INN: Cefuroximum [rINN (la)]
INN: Цефуроксим [rINN (ru)]
INN: ‫[ س ي فوروك س يم‬rINN (ar)]
INN: 头孢呋辛 [rINN (cn)]
Chemical name: (Z)-3-Carbamoyloxymethyl-7-[2-(2-furyl)-2methoxyiminoacetamido]-3-cephem-4-carboxylic acid
Molecular formula: C16H16N4O8S =424.4
CAS: 55268-75-2
ATC code: J01DC02; S01AA27
ATC code (veterinary): QJ01DC02; QJ51DA06; QS01AA27
UNII code: O1R9FJ93ED
Chemical Structure of Cefuroxime
Cefuroxime Axetil
Synonyms: CCI-15641; Cefuroksimas aksetilas; Cefuroksymu aksetyl;
Cefuroxim-axetil; Cefuroxima axetilo; Cefuroximaxetil; Céfuroxime
axétil; Cefuroximum Axetili; Cefuroximum Axetilum;
Kefuroksiimiaksetiili; Sefuroksim Aksetil; セフロキシムアキセチル
BAN: Cefuroxime Axetil [BANM]
USAN: Cefuroxime Axetil
INN: Cefuroxime Axetil [rINNM (en)]
INN: Cefuroxima axetilo [rINNM (es)]
INN: Céfuroxime, Axétil de [rINNM (fr)]
INN: Cefuroximi Axetilum [rINNM (la)]
INN: Цефуроксима Аксетил [rINNM (ru)]
Molecular formula: C20H22N4O10S =510.5
CAS: 64544-07-6
ATC code (veterinary): QJ01DC02; QS01AA27
UNII code: Z49QDT0J8Z
Pharmacopoeias:
In Chin., Eur. (see
), Jpn, and US.
Ph. Eur. 7 (Cefuroxime Axetil). A white or almost white powder. Slightly
soluble in water and in alcohol; soluble in acetone, in ethyl acetate, and
in methyl alcohol. Store in airtight containers. Protect from light.
USP 36 (Cefuroxime Axetil). A mixture of the diastereoisomers of
cefuroxime axetil. A white or almost white powder. The amorphous form
is insoluble in water and in ether; slightly soluble in dehydrated alcohol;
freely soluble in acetone; soluble in chloroform, in ethyl acetate, and in
methyl alcohol. The crystalline form is insoluble in water and in ether;
slightly soluble in dehydrated alcohol; freely soluble in acetone;
sparingly soluble in chloroform, in ethyl acetate, and in methyl alcohol.
Store in airtight containers.
Cefuroxime Sodium
Synonyms: Κεφουροξίμη νατριούχος; Cefuroksimo natrio druska;
Cefuroksym sodowy; Cefuroxim sodná sůl; Cefuroxim-Natrium;
Cefuroxim-nátrium; Cefuroxima sódica; Céfuroxime sodique;
Cefuroximnatrium; Cefuroximum Natricum; Kefuroksiiminatrium;
Sefuroksim Sodyum; セフロキシムナトリウム
BAN: Cefuroxime Sodium [BANM]
INN: Cefuroxime Sodium [rINNM (en)]
INN: Cefuroxima sódica [rINNM (es)]
INN: Céfuroxime Sodique [rINNM (fr)]
INN: Natrii Cefuroximum [rINNM (la)]
INN: Натрий Цефуроксим [rINNM (ru)]
Molecular formula: C16H15N4NaO8S =446.4
CAS: 56238-63-2
ATC code (veterinary): QJ01DC02; QS01AA27
UNII code: R8A7M9MY61
Pharmacopoeias:
In Chin., Eur. (see
), Jpn, and US.
Ph. Eur. 7 (Cefuroxime Sodium). A white or almost white slightly
hygroscopic powder. Freely soluble in water; very slightly soluble in
alcohol. A 1% solution in water has a pH of 5.5 to 8.5. Store in airtight
containers.
USP 36 (Cefuroxime Sodium). A white or faintly yellow powder. Freely
soluble in water; very slightly soluble in alcohol, in chloroform, in ether,
and in ethyl acetate; soluble in methyl alcohol. pH of a 10% solution in
water is between 6.0 and 8.5. Store in airtight containers.
Physicochemical Characteristics (Latest modification: 15-Apr-2004)
Incompatibility and stability
Cefuroxime sodium may be incompatible with aminoglycosides.
References.
(last reviewed 2010-08-20; last modified 2004-03-25)
1. 1. Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole
in an admixture for intravenous infusion. J Clin Pharm Ther 1990; 15:
187–96. PubMed
2. 2. Stiles ML, et al. Stability of ceftazidime (with arginine) and of
cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 1992;
49: 2761–4. PubMed
3. 3. Hebron B, Scott H. Shelf life of cefuroxime eye-drops when dispensed in
artificial tear preparations. Int J Pharm Pract 1993; 2: 163–7.
Adverse Effects and Precautions (Latest modification: 25-Mar-2004)
As for Cefalotin Sodium,
.
Gastrointestinal disturbances, including diarrhoea, nausea, and vomiting,
have occurred in some patients receiving cefuroxime axetil. There have been
rare reports of erythema multiforme, Stevens-Johnson syndrome, and toxic
epidermal necrolysis. Mild to moderate hearing loss has been reported in
some children given cefuroxime for the treatment of meningitis.
Antibiotic-associated colitis (Latest modification: 25-Mar-2004)
For reports of pseudomembranous colitis associated with cefuroxime
axetil, see Cefalotin,
.
Hypersensitivity (Latest modification: 04-Nov-2009)
A report1 of a serum sickness-like reaction to cefuroxime. Similar reactions
have occurred with cefaclor (
represent a class effect.
), although it is unclear whether they
A patient who developed a type-1 hypersensitivity reaction to cefuroxime,
characterised by itchy maculopapular rash, exhibited cross-sensitivity to
cefotaxime and ceftriaxone on patch testing, possibly because of
similarities in the side-chain;2 no cross-sensitivity to cefazolin, cefepime,
cefoxitin, or ceftazidime, or to various penicillins, was seen on testing and
the patient subsequently tolerated doses of amoxicillin and ceftazidime.
The authors noted that cefuroxime had been found in another study to be
the most frequent cause of immediate-type hypersensitivity reactions to
cephalosporins.
1. 1. Katta R, Anusuri V. Serum sickness-like reaction to cefuroxime: a case
report and review of the literature. J Drugs Dermatol 2007; 6: 747–8.
PubMed
2. 2. Varela Losada S, et al. Immediate-type allergic reaction to cefuroxime:
cross-reactivity with other cephalosporins, and good tolerance to
ceftazidime. J Investig Allergol Clin Immunol 2009; 19: 164–5. PubMed
Porphyria (Latest modification: 03-Nov-2011)
The Drug Database for Acute Porphyria, compiled by the Norwegian
Porphyria Centre (NAPOS) and the Porphyria Centre Sweden, classifies
cefuroxime as probably not porphyrinogenic; it may be used as a drug of
first choice and no precautions are needed.1
1. 1. The Drug Database for Acute Porphyria. Available at: online (accessed
15/10/11)
Sodium content (Latest modification: 21-Nov-2003)
Each g of cefuroxime sodium contains about 2.2 mmol of sodium.
Interactions (Latest modification: 25-Mar-2004)
Probenecid reduces the renal clearance of cefuroxime.
Antimicrobial Action (Latest modification: 25-Mar-2004)
Cefuroxime is bactericidal and has a similar spectrum of antimicrobial action
and pattern of resistance to those of cefamandole (
). It is more resistant
to hydrolysis by beta-lactamases than cefamandole, and therefore may be
more active against beta-lactamase-producing strains of, for example,
Haemophilus influenzae and Neisseria gonorrhoeae. However, treatment
failures have occurred in patients with H. influenzae meningitis given
cefuroxime and might be associated with a relatively high minimum
bactericidal concentration when compared with the minimum inhibitory
concentration or with a significant inoculum effect. Reduced affinity of
penicillin-binding proteins for cefuroxime has also been reported to be
responsible for resistance in a beta-lactamase-negative strain of H.
influenzae.
References.
1. 1. Arditi M, et al. Cefuroxime treatment failure and Haemophilus influenzae
meningitis: case report and review of literature. Pediatrics 1989; 84: 132–
5. PubMed
2. 2. Mendelman PM, et al. Cefuroxime treatment failure of nontypable
Haemophilus influenzae meningitis associated with alteration of penicillinbinding proteins. J Infect Dis 1990; 162: 1118–23. PubMed
3. 3. Brown NM, et al. Cefuroxime resistance in Haemophilus influenzae.
Lancet 1992; 340: 552. PubMed
Pharmacokinetics (Latest modification: 27-Jul-2010)
Cefuroxime axetil is absorbed from the gastrointestinal tract and is rapidly
hydrolysed in the intestinal mucosa and blood to cefuroxime; absorption is
enhanced in the presence of food. Peak plasma concentrations occur about 2
to 3 hours after an oral dose. The sodium salt is given by intramuscular or
intravenous injection. Peak plasma concentrations of about
27 micrograms/mL have been achieved 45 minutes after an intramuscular
dose of 750 mg with measurable amounts present 8 hours after a dose. Up
to 50% of cefuroxime in the circulation is bound to plasma proteins. The
plasma half-life is about 70 minutes and is prolonged in patients with renal
impairment and in neonates.
Cefuroxime is widely distributed in the body including pleural fluid, sputum,
bone, synovial fluid, and aqueous humour, but only achieves therapeutic
concentrations in the CSF when the meninges are inflamed. It crosses the
placenta and has been detected in breast milk.
Cefuroxime is excreted unchanged, by glomerular filtration and renal tubular
secretion, and high concentrations occur in the urine. On injection, most of a
dose of cefuroxime is excreted within 24 hours, the majority within 6 hours.
Probenecid competes for renal tubular secretion with cefuroxime resulting in
higher and more prolonged plasma concentrations of cefuroxime. Small
amounts of cefuroxime are excreted in bile.
Plasma concentrations are reduced by dialysis.
Uses and Administration (Latest modification: 09-Apr-2013)
Cefuroxime is a second-generation cephalosporin antibacterial used in the
treatment of infections caused by susceptible Gram-positive and Gramnegative bacteria, including infections of the bones and joints, CNS, skin and
skin structures, respiratory tract, genito-urinary tract (including
gonorrhoea), and Lyme disease. It is also used for surgical infection
prophylaxis. For details of these infections and their treatment, see under
Choice of Antibacterial,
.
Cefuroxime is given orally as the acetoxyethyl ester, cefuroxime axetil, in
the form of tablets or suspension with or after food, or by injection as the
sodium salt. Cefuroxime sodium may be given by deep intramuscular
injection, by slow intravenous injection over 3 to 5 minutes, or by
intermittent or continuous intravenous infusion. Doses of cefuroxime axetil
and cefuroxime sodium are expressed in terms of the equivalent amount of
cefuroxime; 1.20 g of cefuroxime axetil and 1.05 g of cefuroxime sodium are
each equivalent to about 1 g of cefuroxime.
The usual oral dose is 250 mg twice daily; for uncomplicated urinary-tract
infections 125 mg twice daily may be adequate and for respiratory-tract
infections 250 to 500 mg twice daily is recommended. For Lyme disease an
oral dose of 500 mg is given twice daily for 20 days.
By injection the usual dose is 750 mg of cefuroxime every 8 hours but in
more severe infections 1.5 g may be given intravenously every 8, or in some
cases every 6 hours.
Those with pneumonia or with acute exacerbations of chronic bronchitis may
respond to sequential therapy with parenteral cefuroxime 1.5 g twice daily
or 750 mg twice daily respectively, followed by oral cefuroxime 500 mg
twice daily in each case.
For the treatment of meningitis due to sensitive strains of bacteria,
cefuroxime is given intravenously in doses of 3 g every 8 hours.
In the treatment of gonorrhoea, a single dose of 1.5 g by intramuscular
injection, divided between 2 injection sites, has been used. A single 1-g oral
dose of cefuroxime has been given for uncomplicated gonorrhoea. In each
case an oral dose of probenecid 1 g may be given with cefuroxime.
For surgical infection prophylaxis, the usual dose is 1.5 g of cefuroxime
intravenously before the procedure; this may be supplemented by 750 mg
intramuscularly every 8 hours for up to 24 to 48 hours depending upon the
procedure. For total joint replacement, 1.5 g of cefuroxime powder may be
mixed with the methylmethacrylate cement.
The dose of cefuroxime may need to be reduced in patients with renal
impairment, see
. For details of doses in children, see also
.
Reviews.
1. 1. Perry CM, Brogden RN. Cefuroxime axetil: a review of its antibacterial
activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996;
52: 125–58. PubMed
2. 2. Scott LJ, et al. Cefuroxime axetil: an updated review of its use in the
management of bacterial infections. Drugs 2001; 61: 1455–1500. PubMed
Administration in children (Latest modification: 27-Jul-2010)
Cefuroxime may be given to neonates and children for the treatment of
infections caused by susceptible Gram-positive and Gram-negative
bacteria and for surgical prophylaxis. It is given orally (as cefuroxime
axetil), or (as the sodium salt) by injection, either intramuscularly or
intravenously (by slow injection over 3 to 5 minutes, or intermittent or
continuous infusion).
The BNFC 2010/11 suggests the following treatment doses for cefuroxime:
given orally
children 3 months to 2 years of age: 10 mg/kg (to a maximum dose of
125 mg) twice daily
those over 2 years of age: 15 mg/kg (to a maximum dose of 250 mg)
twice daily, or
given parenterally
neonates under 7 days of age: 25 mg/kg every 12 hours
neonates 7 to 21 days of age: 25 mg/kg every 8 hours
neonate 21 to 28 days of age: 25 mg/kg every 6 hours
these doses may be doubled in neonates with severe infections, but
should be given intravenously
children from 1 month of age: 20 mg/kg (to a maximum dose of
750 mg) every 8 hours; this dose may be increased to 50 to 60 mg/kg
(to a maximum dose of 1.5 g) every 6 or 8 hours in severe infection and
cystic fibrosis
For surgical prophylaxis the BNFC 2010/11 suggests that children from the
age of 1 month may be given a dose of 50 mg/kg (to a maximum dose of
1.5 g) intravenously before the procedure; this may be supplemented by
up to 3 further doses of 30 mg/kg (to a maximum dose of 750 mg)
intramuscularly or intravenously at 8-hour intervals for high-risk
procedures.
In the USA, the American Academy of Pediatrics1 suggests the following
doses:
orally
children 1 month and older: 20 to 30 mg/kg in 2 divided doses (to a
maximum daily dose of 1 to 2 g) for mild to moderate infections
intravenously or intramuscularly
children 1 month and older: 75 to 100 mg/kg in 3 divided doses (to a
maximum daily dose of 2 to 4 g) for mild to moderate infections, or 100
to 150 mg/kg in 3 divided doses (to a maximum daily dose of 4 to 6 g)
in severe infections
1. 1. American Academy of Pediatrics. 2009 Red Book: Report of the
Committee on Infectious Diseases, 28th ed. Elk Grove Village, Illinois,
USA: American Academy of Pediatrics, 2009.
Administration in renal impairment (Latest modification: 11-Sep-2009)
Parenteral doses of cefuroxime may need to be reduced in renal
impairment. Licensed product information suggests the following doses
based on creatinine clearance (CC):
CC 10 to 20 mL/minute: 750 mg twice daily
CC less than 10 mL/minute: 750 mg once daily
Patients undergoing haemodialysis should receive an additional 750-mg
dose following each dialysis; those undergoing continuous peritoneal
dialysis may be given 750 mg twice daily.
Preparations (Latest modification: 01-Jul-2013)
Single-ingredient Preparations (Latest modification: 01-Jul-2013)
The symbol ¤ denotes a preparation which is discontinued or no longer
actively marketed.
Argentina: Ceflux¤; Cefogram¤; Cefurox; Ligramex¤; Australia: Zinnat;
Austria: Curocef; Furoxim¤; Zinnat; Belgium: Axetine¤; Cefurim;
Doccefuro¤; Kefurox; Zinacef; Zinnat; Brazil: Cefunorth¤; Cefuran¤;
Keroxime; Medcef; Monocef; Zinacef; Zinnat; Canada: Ceftin; Kefurox¤;
Zinacef¤; Chile: Cerevax; Curocef; Zinnat; China: AoShu; Axetine; Ba Xin;
Ceroxim; Dalixin; Fulexin; Jia Nuo Xin; Jin Mao; Kaidixin; Ku Xin; Li Fu Xin;
Li Jian Xin; Lifurox; Monacef; Pai Wei Xin; Rui Fu Xin; Sipeiding; Supero; Xi
Lu Xin; Xin Li Xin; Xin Lu Xin; Xinfuxin; Yaxing; Youlexin; Yun Tai; Zinacef;
Czech Republic: Axetine; Lifurox¤; Medoxin; Miksor; Xorimax; Zinacef;
Zinnat; Zinoxime¤; Denmark: Axacef¤; Lifurox¤; Zinacef; Zinnat; Finland:
Kefurion¤; Lifurox¤; Zinacef; Zinnat; France: Cepazine¤; Zinnat;
Germany: Cefu¤; Cefudura¤; Cefuhexal; Cefurax¤; Cefuro-Puren¤;
Cefurox-Reu¤; Cefurox-Wolff¤; Cefurox¤; Elobact; Zinacef¤; Zinnat;
Greece: Anaptivan; Cefoprim; Cefur; Cefuretil; Cefuroprol; Cerofene;
Ceruxim; Cupax; Ecoline; Feacef; Foucacillin; Fredyr; Furaxil; Galemin;
Genephoxal; Gonif; Helatocil; Interbion; Lyprovir; Medoxem; Mevecan;
Mosalan; Nelabocin; Nipogalin; Normafenac; Receant; Saxetil; Sedopan;
Vekfazolin; Yokel; Zagorine; Zetagal; Zilisten; Zinacef; Zinadol; Hong
Kong: Anikef¤; Axacef; Axetine¤; Axim; Ceflour; Quali-Cefurnat; Sefuxim;
Xorimax; Zinacef; Zinnat; Hungary: Cefurin¤; Ceroxim; Cexim¤; Xorim;
Xorimax; Zinacef; Zinnat; India: Actum; Adexim; Altacef; Altum; Anorex;
Arixime; Atom; Aucee; Axacef; Axeptil; Axeris; Axetim; Axtl; Bacticef;
Barocef; Bencef; Bigcef; Biocef; Bullcef; C-Furo; C-Tri-T; Cascef; Ceax; CefVepan; Cefakind; Cefam; Cefar; Cefasyn; Cefexl; Cefies; Cefking; Ceflet;
Cefob; Cefogen; Cefoprim; Ceforim; Ceforox; Cefos; Cefoxim; Cefpil; Cefta;
Ceftab; Ceftal; Ceftra; Ceftum; Cefu; Cefubir; Cefucin; Cefucos; Cefunis;
Cefupet; Cefurin; Cefusym; Cefutab-O; Cefuvik; Cefyrex; Cefzim; Ceplex;
Cepokem; Cerom; Ceroxitum; Cesai; Cetil; Ceurox; Cilixem; CTrox;
Curoxim; Cutil; Cuxim; Daltum; Dericef; Difu; Duxim; Edrucef; Ethicef;
Evercef; Exeption; Exime; Flamicef; Forcef; Forcez; Forex; Forkem; Fucef;
Furion; Furobid; Furomax; Furome; Furox; Furoxil; Fydoroxim; Glyph-ZM;
Gocef; I-M-Sure; Iflacef; Insifu; Intracef; Iviroxime; Jaxe; Joxcy; Kaircef;
Kaxitel; Kefstar; Kefuel; Kem; Kincef; Klime; L-Tum; Lazocin; Luroxime;
Magna; Magnacef; Martec; Maxim; Maxtum; Metump; Milcef; Neftum-AXT;
Neroxim; Nifoxime; Novaroxim; Ocef; Omnixim; Oruf; Supacef; Indonesia:
Anbacim; Cefurox¤; Celocid; Cethixim; Kalcef; Kenacef¤; Oxtercid; Roxbi¤;
Sharox; Soxime; Zinacef¤; Zinnat; Ireland: Ceftal; Zinacef; Zinnat; Israel:
Cefurax; Ceroxim; Kefurim; Zinacef; Zinnat; Italy: Biociclin¤; Biofurex¤;
Bioxima¤; Cefamar¤; Cefoprim¤; Cefumax¤; Cefur¤; Cefurex¤; Cefurin;
Colifossim¤; Curoxim; Deltacef¤; Duxima; Gibicef¤; Ipacef¤; Itorex; Kefox¤;
Kesint¤; Lafurex¤; Lamposporin¤; Medoxim¤; Oraxim; Polixima¤; Supero;
Tilexim; Ultroxim¤; Zinnat; Zinocep; Zoref; Malaysia: Altacef; Anikef;
Ceflour; Efurox; Furoxime; Vaxcel Cefuroxime; Xorimax; Xylid; Zinacef;
Zinnat; Zocef; Mexico: Cefabiot; Cefagen; Cefuracet; Cetoxil; Froxal;
Fucerox; Furobioxin; Lemoxin¤; Magnaspor; Novador; Ximaken; Xorufec;
Zinnat; Netherlands: Aprokam; Cefofix¤; Zinacef; Zinnat; Norway:
Lifurox¤; Zinacef; New Zealand: Axetine; Zinacef; Zinnat; Philippines:
Aeruginox; Altacef; Ambixime; Axet; Axurocef; Bactipoz; Betcef; C-Tri T;
Cefogen; Ceftil; Cefucil¤; Cefumax; Cefurex; Cefuzime; Cervin; Cesavess;
Cidokez; Cimex; Clovixime; Curecef; Darcef; Ecocef; Educef; Elixime;
Emixor; Eoroxime; Eroxmit; Eurimax; Finax; Fubaxyn¤; Furocef; Furocem;
Furomax; Furoxim¤; Furoxy; Harox; Ifurax; Infekor; Jectocef; Kaftax;
Kefezy; Kefox; Kefstar; Kefsyn; Kefurox; Keunzef; Lasuzef; Laxinat;
Loxatrel¤; Medxil; Medxime; Medzyme; Microzef; Panaxim; Panjecxime;
Pheoronex; Plerozef; Profurex; Rexofen; Rezafil; Robisef; Rocef; Romicef;
Rovix; Roxetil; Roxicef; Roxime; Roxym¤; Rucef; Ruxim; Sharox¤; Shincef;
Teikeden; Unoximed; Vitaroxima; Xorimax; Zefcid; Zefsur; Zefur; Zefuxim;
Zegen; Zenoxim; Zinacef; Zinaf; Zinnat; Zoltax; Zurenix; Poland:
Biofuroksym; Bioracef; Ceroxim; Novocef; Plixym¤; Tarsime; Xelacef;
Xorim¤; Xorimax; Zamur; Zinacef; Zinnat; Zinoxx; Portugal: Antibioxime;
Axacef; Cefaricida¤; Cefofix¤; Cefrix¤; Condronac; Curoxime; Famicef;
Furaxetil¤; Lusocef¤; Pluscef¤; Saracef; Zipos; Zoref; Russia: Antibioxim
(Антибиоксим); Axetine (Аксетин); Cefurabol (Цефурабол); Cefurus
(Цефурус); Cetyl (Цетил); Kefstar (Кефстар); Ketocef (Кетоцеф); Proxime
(Проксим); Supero (Суперо); Xorim (Ксорим); Zinacef (Зинацеф); Zinnat
(Зиннат); South Africa: Auroxime; Betaroxime; Cefasyn; Cefu-Hexal;
Ceroxim; Cipofix; CuroAx; Intracef¤; Lifurom¤; Medaxime; Zefroxe;
Zefurime; Zinacef; Zinnat; Zinoxime; Singapore: Bearcef; Ceftil; Cefxin;
Shincef; Xorimax; Zinacef; Zinnat; Spain: Curoxima; Lifurox¤; Nivador¤;
Selan; Zinnat; Sweden: Axacef¤; Lifurox¤; Zinacef; Zinnat¤; Switzerland:
Cefurim; Zinacef; Zinat; Thailand: Axetine¤; Axurocef¤; C-Tri T; Cefamar¤;
Cefogen¤; Cefurim; Farmacef; Furoxime; Magnaspor; Neurox; Sefuxim;
Zinacef; Zinnat; Zocef; Zonef¤; Turkey: Aksef; Cefaks; Cefatin; Cefurol;
Enfexia; Multisef; Oraceftin; Sefaktil; Seffur; Sefuroks; Zinnat; United Arab
Emirates: Cefuzime; United Kingdom: Aprokam; Zinacef; Zinnat;
Ukraine: Aksef (Аксеф); Biofuroksym (Биофуроксим)¤; Cefoctam
(Цефоктам)¤; Cefumax (Цефумакс); Cefutil (Цефутил); Enfexia
(Энфексия); Kimacef (Кимацеф); Mikrex (Микрекс); Spizef (Спизеф);
Zinacef (Зинацеф); Zinnat (Зиннат); United States: Ceftin; Kefurox¤;
Zinacef; Venezuela: Xorim; Zencef; Zinacef; Zinnat;
Multi-ingredient Preparations (Latest modification: 17-Jan-2012)
The symbol ¤ denotes a preparation which is discontinued or no longer
actively marketed.
India: Bactocef; C-Tri EM; Cefos-S; Covatil-CV; Intracef-CV; Ocef-CV;
Pharmacopoeial Preparations (Latest modification: 06-Feb-2013)
BP 2013: Cefuroxime Axetil Oral Suspension; Cefuroxime Axetil Tablets;
Cefuroxime Eye Drops; Cefuroxime Injection; Cefuroxime Intracameral
Injection; USP 36: Cefuroxime Axetil for Oral Suspension; Cefuroxime Axetil
Tablets; Cefuroxime for Injection; Cefuroxime Injection;
Martindale: The Complete Drug Reference © 2013 The Pharmaceutical Press.
MedicinesComplete © The Pharmaceutical Press 2013

Cefuroxime

Transcripción

Documentos relacionados

Spanish - PICA Head Start